NCT06179537View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

October 22, 2021

Study Completion Date

November 21, 2021

Conditions

Healthy

Interventions

DRUG

BLU-5937

Single and multiple doses assessment

Trial Locations (1)

SE1 1YR

Richmond Pharmacology Ltd., London

All Listed Sponsors

lead

Bellus Health Inc. - a GSK company

INDUSTRY